Search Results - "Wollbratt, M."

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus by Morrow, L. A., Leonsson-Zachrisson, M., Ericsson, H., Wollbratt, M., Knutsson, M., Hompesch, M., Norjavaara, E.

“…Aims To assess the safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator AZD1656 in patients with type 2…”
Get full text

Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects by Johansson, S, Cullberg, M, Eriksson, U G, Elg, M, Dunér, K, Jensen, E, Wollbratt, M, Wåhlander, K

“…The novel oral anticoagulant AZD0837 is currently in clinical development for the prevention of stroke and systemic embolic events in patients with atrial…”
Get full text

No Pharmacokinetic or Pharmacodynamic Interaction Between Digoxin and the Oral Direct Thrombin Inhibitor Ximelagatran in Healthy Volunteers by Sarich, Troy C., Schützer, Kajs-Mariey, Wollbratt, Maria, Wall, Ulrika, Kessler, Eva, Eriksson, Ulf G.

“…The interaction potential of digoxin and ximelagatran, an oral direct thrombin inhibitor being developed for the prevention and treatment of thromboembolic…”
Get full text

The usefulness of sugar surfactants as solubilizing agents in parenteral formulations by Söderlind, Erik, Wollbratt, Maria, von Corswant, Christian

“…The usefulness of sugar surfactants as solubilizing agents was assessed and compared to commercial polyoxyethylene-based surfactants. The sugar surfactants…”
Get full text

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects by Sarich, Troy C, Wolzt, Michael, Eriksson, Ulf G, Mattsson, Christer, Schmidt, Alice, Elg, Susanne, Andersson, Magnus, Wollbratt, Maria, Fager, Gunnar, Gustafsson, David

“…The effects of ximelagatran, an oral direct thrombin inhibitor (DTI), recombinant hirudin (r-hirudin) and enoxaparin on thrombin generation and platelet…”
Get full text

No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran by SARICH, Troy C, TENG, Renli, PETERS, Gary R, WOLLBRATT, Maria, HOMOLKA, Robert, SVENSSON, Mia, ERIKSSON, Ulf G

“…Ximelagatran, an oral direct thrombin inhibitor, is currently in clinical development for the prevention and treatment of thromboembolic disease. Following…”
Get full text

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects by WOLZT, Michael, WOLLBRATT, Maria, SVENSSON, Mia, WAHLANDER, Karin, GRIND, Margaretha, ERIKSSON, Ulf G

“…To investigate the influence of nonvalvular atrial fibrillation (NVAF) on the pharmacokinetic (PK) properties of the oral direct thrombin inhibitor…”
Get full text

No clinically significant interactions between the oral direct thrombin inhibitor ximelagatran and amiodarone, atorvastatin, or digoxin by Dorani, H., Schützer, K., Wollbratt, M., Sarich, T. C., Eriksson, U. G., Teng, R., Ohlsson, L., Kessler, E., Wall, U., Kalies, I., Hamer, J. E.

“…Background The oral direct thrombin inhibitor ximelagatran has shown clinical benefit in patients with atrial fibrillation at risk of stroke. The potential for…”
Get full text